Post-Discharge Malaria Chemoprevention: A Statistical Analysis of Effectiveness and Challenges

[1] Dhanasri, [2] Sri Priya, [3] Shruthi, Manjunath, [4]Rajesh Kumar K V,
[1 ,2,3] Postgraduate Student, MBA- Business Analytics, School of Business, Woxsen University
[4]Associate Professor, Department of Analytics, School of Business, Woxsen University

ABSTRACT

Post-discharge malaria chemoprevention (PDMC) has become a critical intervention in the prevention of morbidity and mortality among children recovering from severe malaria and anaemia. Statistical estimates from various studies show that PDMC can decrease hospital readmissions by 19% and avert up to 38,600 malaria-related readmissions per year in high-risk areas like upland Tanzania. In addition, estimates indicate that the treatment of 2–5 children with PDMC averts a hospital readmission, and fewer than 100 treatments avert a death. In Burkina Faso, Seasonal Malaria Chemoprevention (SMC), a similar intervention, decreased cases of malaria by 51%, anaemia by 32%, and fever by 46%.While these results are promising, limitations include drug resistance, logistical impediments to roll-out, and heterogeneity of community acceptance. Stakeholder dialogue and WHO recommendations emphasize the need for adaptive strategies, including roll-out of PDMC to children with severe malaria, roll-out in the community, and monitoring of resistance. These initiatives underlie Sustainable Development Goal (SDG) 3—Good Health and Well-being—by closing post-discharge risks, leveling playing fields of access to lifesaving treatment, and fortifying strong health systems to battle death from childhood malaria. These gaps can be surmounted by augmenting policy strengthening, intensified follow-up action, and targeted deployment of drugs for the purpose of capitalizing on PDMC as a cost-effective, replicable, and sustainable malaria-control intervention for malaria-endemic countries.

PROBLEM STATEMENT AND INTRODUCTION

PROBLEM STATEMENT:
Post-Discharge Malaria Chemoprevention (PDMC) reduces malaria recurrence, but its real-world effectiveness is limited by poor patient adherence, drug resistance, and weak healthcare delivery systems, demanding urgent strategies to enhance implementation and outcomes.

INTRODUCTION:
Post-Discharge Malaria Chemoprevention (PDMC) has proven effective in reducing malaria recurrence and hospital readmissions among children recovering from severe malaria. However, despite its clinical success, the implementation of PDMC faces several real-world challenges. Poor patient adherence to medication regimens, emerging drug resistance, and inadequate rural healthcare infrastructure significantly undermine the potential benefits of this intervention. Socioeconomic barriers and logistical difficulties further complicate widespread adoption and effective monitoring. These challenges contribute to persistently high rates of reinfection and mortality, particularly in malaria-endemic regions. Addressing these issues is crucial to enhance the impact of PDMC and align with the global health goal of reducing child mortality. This study focuses on identifying the key barriers and recommending strategies to strengthen PDMC implementation.

METHODS AND ANALYSIS



- **Datasets:** Comprehensive analysis of three PDMC datasets.
- **Data Variables Collected:** Age, sex, weight, infection type, severity, hospitalization, chemoprevention regimen, adherence, reinfection, adverse events, readmissions, mortality.
- **Data Preparation:** Data cleaning, missing value imputation, outlier handling, encoding categorical variables.
- **Statistical and ML Models Applied:**
  - Linear Regression: Hospital stay, adherence, reinfection timing.
  - Logistic Regression: Reinfection risk prediction.
  - Decision Trees: Decision pathways analysis.
  - Random Forest: Accuracy boost, feature importance.
  - SVM: Patient group classification.
  - Naive Bayes: Probabilistic predictions.
  - Clustering: Patient risk segmentation.
- **Model Validation and Evaluation:** k-fold cross-validation; metrics: Accuracy, Precision, Recall, F1 Score, AUC-ROC.
- **Feature Analysis:** Feature importance derived from ensemble models.
- **Tools Used:** Python (Pandas, Scikit-learn, NumPy, Matplotlib, Seaborn), Tableau (visualizations), SPSS (descriptive statistics, hypothesis testing).
- **Ethical Considerations:** Patient data anonymized; full ethical compliance maintained.

PROPOSED RESEARCH IN FLOWCHART



RESULTS AND DISCUSSIONS



Figure 4.2 "Statistical Distribution and Boxplot Analysis of Patient Health Data"

Results:
•Mean patient age: 33–35 years; major infections: P. falciparum, P. vivax, mixed.
•Average hospitalization: 6.5–7.8 days; severe cases up to 14 days.
•Chemoprevention: DHA-PPQ, Amodiaquine, SP; 2–3 doses per patient.
•Adherence: 44–47% fully adhered; non-adherence linked to >50% reinfection.
•Reinfection: Mean 90 days post-discharge; early reinfections in 5–14 days.
•Adverse events: Rash, dizziness, fatigue impacted treatment adherence.
•Mortality and readmissions: 5–6% mortality; readmissions from anaemia, reinfection, adverse reactions.

Discussion:
While PDMC effectively reduces malaria morbidity and mortality post-discharge, multiple operational challenges undermine its success. Drug resistance, limited healthcare accessibility in rural settings, suboptimal patient education, and weak monitoring mechanisms remain significant hurdles. Future implementations must address these gaps by strengthening healthcare systems, ensuring drug availability, improving community awareness, and enhancing patient follow-up mechanisms.

CONCLUSION

Post-Discharge Malaria Chemoprevention (PDMC) is a highly effective strategy to reduce malaria-related hospitalisations, reinfections, and deaths among children, particularly in malaria-endemic regions. Statistical evidence confirms its significant potential to improve child health outcomes. However, the real-world effectiveness of PDMC is constrained by critical challenges such as emerging drug resistance, logistical hurdles in rural and resource-limited settings, weak healthcare infrastructure, insufficient patient follow-up, and low community awareness and acceptance.To unlock the full potential of PDMC, there is an urgent need to strengthen national health policies, ensure uninterrupted drug supply chains, launch widespread community education initiatives, and build healthcare capacities at the grassroots level. Integrating PDMC programs into broader national malaria control strategies and enhancing monitoring mechanisms for treatment adherence and drug resistance will be crucial.With coordinated efforts among governments, healthcare providers, and international organizations, and through sustained investment and innovation, PDMC can evolve into a scalable, cost-effective, and sustainable intervention that significantly contributes to reducing the global malaria burden and supports the achievement of Sustainable Development Goal 3 — Good Health and Well-being.

REFERENCES

1) Tusting, L. S., Gething, P. W., Gibson, H. S., Greenwood, B., Knudsen, J., Lindsay, S. W., & Bhatt, S. (2020). Housing and child health in sub-Saharan Africa: A cross-sectional analysis. *PLOS Medicine*, *17*(3), e1003359.

2) Black, M. M., Walker, S. P., Fernald, L. C. H., Andersen, C. T., DiGirolamo, A. M., Lu, C., McCoy, D. C., Fink, G., Shawar, Y. R., Shiffman, J., Devercelli, A. E., Wodon, Q. T., Vargas-Barón, E., & Grantham-McGregor, S. (2022). Advancing early childhood development: From science to scale 2. *The Lancet Child & Adolescent Health*, *6*(8), 545–558.

3) Aydin-Schmidt, B., Mohon, A. N., Thriemer, K., & Holmström, P. (2024). Prevalence of asymptomatic malaria and comparison of diagnostic tools in a low-endemic setting in Ethiopia. *Malaria Journal*, *23*, Article 120.

4) Allwood, B. W., Calligaro, G. L., Stolbrink, M., Van Der Zalm, M. M., & Dheda, K. (2023). South African perspectives on post-acute sequelae of COVID-19. *The Lancet Regional Health – Africa*, *22*, 100693.

5) Gachot, B., Senneville, E., Terzi, N., & Dubée, V. (2015). Bloodstream infection in patients with diabetic foot infections: Clinical features and outcomes. *BMC Infectious Diseases*, *15*, Article 441.

REVIEWERS

1. NAME: _____
DESIGNATION _____
SCHOOL _____
------/10
REMARKS _____

2. NAME: _____
DESIGNATION _____
SCHOOL _____
------/10
REMARKS _____

3. NAME: _____
DESIGNATION _____
SCHOOL _____
------/10
REMARKS _____

4. NAME: _____
DESIGNATION _____
SCHOOL _____
------/10
REMARKS _____

5. NAME: _____
DESIGNATION _____
SCHOOL _____
------/10
REMARKS _____